Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Intapp, Inc. | 10%+ Owner | Common stock | 17.1M | $772M | $45.02 | Nov 17, 2023 | Indirect |
Poshmark, Inc. | 10%+ Owner | Class A common stock | 3.97M | $71.1M | $17.90 | May 25, 2022 | Indirect |
SES AI Corp | 10%+ Owner | Class A Common Stock | 2.3M | $1.91M | $0.83 | Sep 20, 2024 | By Fund |
FTS International, Inc. | 10%+ Owner | Warrant (right to buy) | 938K | $561K | $0.60 | Aug 26, 2021 | Indirect |
Akili, Inc. | 10%+ Owner | Common Stock, par value $0.0001 | 0 | $0 | $0.42 | Jul 2, 2024 | Indirect |
Pear Therapeutics, Inc. | 10%+ Owner | Class A Common Stock | 26.8M | Dec 3, 2021 | Indirect | ||
Akili, Inc. | 10%+ Owner | Earnout Shares | 0 | Jul 2, 2024 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
SES | SES AI Corp | Sep 19, 2024 | 2 | -$631K | 4 | Sep 23, 2024 | 10%+ Owner |
SES | SES AI Corp | Sep 17, 2024 | 2 | -$2.44M | 4 | Sep 19, 2024 | 10%+ Owner |
SES | SES AI Corp | Sep 13, 2024 | 2 | -$241K | 4 | Sep 17, 2024 | 10%+ Owner |
AKLI | Akili, Inc. | Jul 2, 2024 | 2 | $0 | 4 | Jul 5, 2024 | 10%+ Owner |
INTA | Intapp, Inc. | Nov 17, 2023 | 1 | -$97.5M | 4 | Nov 20, 2023 | 10%+ Owner |
INTA | Intapp, Inc. | May 22, 2023 | 1 | -$87.1M | 4 | May 22, 2023 | 10%+ Owner |
AKLI | Akili, Inc. | Aug 19, 2022 | 0 | $0 | 3 | Aug 26, 2022 | 10%+ Owner |
POSH | Poshmark, Inc. | May 25, 2022 | 1 | -$21.3M | 4 | May 27, 2022 | 10%+ Owner |
SES | SES AI Corp | Feb 3, 2022 | 0 | $0 | 3 | Feb 14, 2022 | 10%+ Owner |
PEARQ | Pear Therapeutics, Inc. | Dec 3, 2021 | 0 | $0 | 3 | Dec 9, 2021 | 10%+ Owner |
FTSI | FTS International, Inc. | Aug 26, 2021 | 2 | -$856K | 4 | Aug 30, 2021 | 10%+ Owner |
POSH | Poshmark, Inc. | Jul 9, 2021 | 2 | $0 | 4 | Jul 13, 2021 | 10%+ Owner |
INTA | Intapp, Inc. | Jul 2, 2021 | 4 | $49.9M | 4 | Jul 6, 2021 | 10%+ Owner |
INTA | Intapp, Inc. | Jun 29, 2021 | 0 | $0 | 3 | Jun 29, 2021 | 10%+ Owner |